Parent’s age at onset may help predict Alzheimer’s disease biomarker levels
In their study, the investigators analyzed amyloid-1-42 in cerebrospinal fluid (CSF) specimens from 101 cognitively unimpaired individuals enrolled in the Presymptomatic Evaluation of Novel or Experimental Treatments for Alzheimer Disease (PREVENT-AD) cohort. They estimated each participant’s closeness to their parent’s symptom onset by subtracting their relative’s onset age from their current age. Using CSF and Pittsburgh compound B carbon 11–labeled positron emission tomography (PIB-PET) amyloid- biomarkers, they performed analyses again in the Adult Children Study (ACS) and Wisconsin Registry for Alzheimer Prevention (WRAP) cohorts. {read more here}
Researchers evaluated associations between self-awareness status and baseline levels of brain β-amyloid (Aβ) as measured by [18F] florbetapir PET, and cerebrospinal fluid (CSF) levels of Aβ, total tau, and phosphorylated tau (p-tau). {read more here}
Axumin (fluciclovine F 18) injection has been added to the National Comprehensive Cancer Network® (“NCCN”) Clinical Practice Guidelines in Oncology for Prostate Cancer. These updated NCCN Guidelines state that F-18 fluciclovine PET/CT or PET/MRI should be considered in the clinical workup of patients with recurrence or progression of their prostate cancer. {read more here}
Psoriasis patients were randomly divided into two groups, with 21 patients in the placebo group and 22 patients receiving the treatment. The primary outcome was aortic inflammation, as measured by 18-FDG-PET/CT scans — an imaging technique that reveals inflammation in the aorta. The imaging was performed before treatment and at 12 weeks. The treatment group saw a 6.6 percent decrease in aortic inflammation, while the placebo group saw a 12 percent increase, meaning the drug is responsible for a 19 percent improvement relative to untreated patients. {read more here}